Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)
Latest Information Update: 30 Mar 2022
At a glance
- Drugs Spartalizumab (Primary) ; Canakinumab; CJM 112; Nazartinib; Trametinib
- Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Non-small cell lung cancer; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 27 Apr 2021 Status changed from active, no longer recruiting to completed.
- 17 Mar 2021 Planned End Date changed from 1 Mar 2021 to 18 Mar 2021.
- 17 Mar 2021 Planned primary completion date changed from 1 Mar 2021 to 18 Mar 2021.